Navigation Links
Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy
Date:1/27/2009

Larynx cancer patients treated with alternating cycles of chemotherapy and radiation have similar outcomes to patients treated with chemotherapy followed by radiation, according to data from a randomized controlled trial in the January 27 online issue of the Journal of the National Cancer Institute.

Previous trials in patients with locally advanced larynx cancer showed that chemotherapy followed by radiation was as effective as total removal of the larynx, known as laryngectomy, in terms of overall and disease-free survival and that this sequential therapy provided better quality of life. Subsequent trials indicated that concurrent administration of chemotherapy and radiation resulted in a statistically significant improvement in larynx preservation but was associated with more serious acute toxicity and possibly long term side effects.

To try to improve patient survival without increasing side effects, Jean Lefebvre, M.D., of the Centre Oscar Lambret in Lille, France, and colleagues in the European Organization for Research and Treatment of Cancer enrolled 450 patients with larynx or hypopharynx cancer in a randomized controlled trial. Patients received either chemotherapy followed by radiation or alternating cycles of radiation and chemotherapy.

With a median follow-up of 6.5 years, there was no significant difference in clinical outcomes between the two treatment groups. Larynx preservation, overall survival, and progression-free survival were similar for patients treated with sequential and alternating chemotherapy and radiation.

"The aim of our trial was to identify a regimen that would mimic concomitant chemotherapy and radiotherapy without its increased toxic effects," the authors write. "Although we achieved the latter goalefficacy was not improved." Given the results of this and several other recently-completed trials, the authors conclude that an optimal approach for larynx-preserving therapy has not been identified.

In an accompanying editorial, Arlene Forastiere, M.D., and Andy Trotti, M.D., of the Sidney Kimmel Cancer Center at Johns Hopkins University in Baltimore and the H. Lee Moffitt Cancer Center at the University of South Florida in Tampa, respectively, concur with that conclusion. The editorialists put the newly-reported data into context, reviewing other trials in the field. They note, however, that because the field currently lacks shared definitions and endpoints, synthesis of data from all the trials is difficult.

"In summary, the [current] trial showed no advantage for alternating chemotherapy and radiotherapy over traditional cisplatin plus 5-fluorouracil induction chemotherapy in hypopharynx cancer," the editorialists write. "More effective and less toxic approaches are needed. This trial also illustrates the need for common definitions and metrics to facilitate interpretation and to compare results across trials."


'/>"/>

Contact: Caroline McNeil
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Alternating mammography and MRI may be best for high-risk women
2. How chemotherapy drugs block blood vessel growth, slow cancer spread
3. UNC study supports role of circadian clock in response to chemotherapy
4. Gene Governs Response to Leukemia Chemotherapy
5. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
6. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
7. Studies show novel device may enhance chemotherapy treatment in brain tumors
8. Iressa as Good as Chemotherapy for Lung Cancer
9. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
10. The Neuropathy Associations Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
11. SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 21, 2017 , ... Dental visits are often low ... you've seen a dentist, it's time for a dental checkup. The American Dental ... year. , Dental checkups are a relatively easy procedure that involves visually inspecting ...
(Date:5/19/2017)... , ... May 19, 2017 , ... ... health community, Queens University of Charlotte recently began recruitment efforts for the inaugural ... arms students with the skills, knowledge and expertise to approach and address the ...
(Date:5/19/2017)... ... May 19, 2017 , ... When Kyle Busch graduates from Kansas ... already appear on two major research studies that could impact the health of young ... Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team trying to discover ...
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... The Hill ... to families and entrepreneurs throughout the California Central Valley, is announcing a joint charity ... raising community support for a local kid’s camp event. , The Boys and Girls ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... class of Beckman Young Investigators: , Victor Acosta, Ph.D. - University of New ... Dan Fu, Ph.D. - University of Washington, Erik Grumstrup, Ph.D. - Montana Stata ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/12/2017)... , May 12, 2017  The China and Canada ... technology that consumes less water, energy and detergent, and features a ... product LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s ... ... LaughingU, is compact, and does not require an external water inlet. ...
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
Breaking Medicine Technology: